These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 38736991)

  • 1. Genomic Surveillance for SARS-CoV-2 Variants: Dominance of XBB Replacement - China, January-June 2023.
    Feng Y; Su Q; Li L; He X; Niu P; Guo X; Zhao X; Tang J; Jia Z; Wang J; Wu C; Xia B; Chen Z; Wu Y; Yang J; Chen S; Chen C; Wang S; Dong X
    China CDC Wkly; 2024 Apr; 6(15):324-331. PubMed ID: 38736991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance and Analysis of SARS-CoV-2 Variant Importation - China, January-June 2022.
    Feng Y; Zhao X; Yin Z; Wu C; Chen Z; Nie K; A R; Li L; Niu P; Wang J; Wu Y; Wang S; Wang D; Tan W; Wang H; Ma X; Gao GF; Chen C; Xu W
    China CDC Wkly; 2022 Dec; 4(50):1136-1142. PubMed ID: 36751558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and diversity of imported severe acute respiratory syndrome coronavirus 2 variants in China, 2021-2022.
    Feng Y; Zhao X; Chen Z; Wu Y; Li L; Wu C; Nie K; Yang X; Niu P; Wang J; Wang S; Chen C
    J Med Virol; 2024 May; 96(5):e29664. PubMed ID: 38727137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
    Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Surveillance for SARS-CoV-2 - China, September 26, 2022 to January 29, 2023.
    Wang S; Niu P; Su Q; He X; Tang J; Wang J; Feng Y; Chen C; Zhao X; Chen Z; Wang W; Yin Z; Wu Y; Wu C; Li L; Cui A; Zhang Y; Long C; Yang X; Zhang Z; Bo H; Xu W; Sars-CoV-Genome Working Group
    China CDC Wkly; 2023 Feb; 5(7):143-151. PubMed ID: 37009519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.
    Ma KC; Shirk P; Lambrou AS; Hassell N; Zheng XY; Payne AB; Ali AR; Batra D; Caravas J; Chau R; Cook PW; Howard D; Kovacs NA; Lacek KA; Lee JS; MacCannell DR; Malapati L; Mathew S; Mittal N; Nagilla RR; Parikh R; Paul P; Rambo-Martin BL; Shepard SS; Sheth M; Wentworth DE; Winn A; Hall AJ; Silk BJ; Thornburg N; Kondor R; Scobie HM; Paden CR
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):651-656. PubMed ID: 37319011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Surveillance for SARS-CoV-2 Variants of Concern from Imported COVID-19 Cases - the Mainland of China, 2021.
    Feng Y; Zhao X; Chen Z; Nie K; Yin Z; Xia Y; Wang J; Niu P; A R; Li L; Wang D; Tan W; Ma X; Wang S; Wang H; Gao GF; Chen C; Xu W
    China CDC Wkly; 2022 Aug; 4(31):680-684. PubMed ID: 36059791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regional genomic surveillance program is implemented to monitor the occurrence and emergence of SARS-CoV-2 variants in Yubei District, China.
    Liu F; Deng P; He J; Chen X; Jiang X; Yan Q; Xu J; Hu S; Yan J
    Virol J; 2024 Jan; 21(1):13. PubMed ID: 38191416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Genomic Surveillance of SARS-CoV-2 at Xiamen International Airport and the Port of Xiamen Reveals the Importance of Incoming Travelers in Lineage Diversity.
    You R; Wu R; Wang X; Fu R; Xia N; Chen Y; Yang K; Chen J
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineage dissemination in Brazil in 2023.
    Arantes I; Gomes M; Ito K; Sarafim S; Gräf T; Miyajima F; Khouri R; de Carvalho FC; de Almeida WAF; Siqueira MM; Resende PC; Naveca FG; Bello G;
    Microbiol Spectr; 2024 Mar; 12(3):e0383123. PubMed ID: 38315011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural evolution of SARS-CoV-2 omicron in human receptor recognition.
    Zhang W; Shi K; Geng Q; Herbst M; Wang M; Huang L; Bu F; Liu B; Aihara H; Li F
    J Virol; 2023 Aug; 97(8):e0082223. PubMed ID: 37578233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Surveillance of SARS-CoV-2 in Malaysia during the Era of Endemic COVID-19.
    Lee TY; Lim WF; Ang GY; Yu CY
    Life (Basel); 2023 Jul; 13(8):. PubMed ID: 37629505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 - the public health challenges.
    Velavan TP; Ntoumi F; Kremsner PG; Lee SS; Meyer CG
    Int J Infect Dis; 2023 Mar; 128():307-309. PubMed ID: 36681145
    [No Abstract]   [Full Text] [Related]  

  • 19. Low neutralization of SARS-CoV-2 Omicron BA.5.2.48, BF.7.14, XBB.1 subvariants by homologous or heterologous booster.
    Li J; Mao H; Song W; Chen Y; Feng Y; Li J; Su L; Li X; Shi W; Wu Y; Huang C; Zhang Y; Chen K
    J Med Virol; 2023 Dec; 95(12):e29306. PubMed ID: 38084772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.